{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:57:25Z","timestamp":1776329845686,"version":"3.50.1"},"reference-count":19,"publisher":"Baskent University","issue":"Suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.6002\/ect.mesot2021.o27","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T02:45:14Z","timestamp":1649299514000},"page":"69-73","source":"Crossref","is-referenced-by-count":4,"title":["Fludrocortisone Among Adult Renal Transplant Recipients With Persistent Hyperkalemia: Single-Center Experience"],"prefix":"10.6002","volume":"20","author":[{"given":"Osama A.","family":"Gheith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Dahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman Maher","family":"Nagib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Adel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Elserwy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam","family":"Sobhy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"AbdelMonem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasaneen","family":"Abo Atya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"orki","family":"Al-Otaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Almalki B, Cunningham K, Kapugi M, Kane C, Agrawal A. Management of hyperkalemia: A focus on kidney transplant recipients. Transplant Rev (Orlando). 2021;35(2):100611. doi:10.1016\/j.trre.2021.100611","DOI":"10.1016\/j.trre.2021.100611"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Higgins R, Ramaiyan K, Dasgupta T, et al. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. Nephrol Dial Transplant. 2004;19(2):444-450. doi:10.1093\/ndt\/gfg515","DOI":"10.1093\/ndt\/gfg515"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Menegussi J, Tatagiba LS, Vianna JGP, Seguro AC, Luchi WM. A physiology-based approach to a patient with hyperkalemic renal tubular acidosis. J Bras Nefrol. 2018;40(4):410-417. doi:10.1590\/2175-8239-JBN-3821","DOI":"10.1590\/2175-8239-jbn-3821"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Farouk SS, Rein JL. The many faces of calcineurin inhibitor toxicity-what the FK? Adv Chronic Kidney Dis. 2020;27(1):56-66. doi:10.1053\/j.ackd.2019.08.006","DOI":"10.1053\/j.ackd.2019.08.006"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Tumlin JA, Sands JM. Nephron segment-specific inhibition of Na+\/K(+)-ATPase activity by cyclosporin A. Kidney Int. 1993;43(1):246-251. doi:10.1038\/ki.1993.38","DOI":"10.1038\/ki.1993.38"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Heering PJ, Kurschat C, Vo DT, Klein-Vehne N, Fehsel K, Ivens K. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression. Clin Transplant. 2004;18(2):186-192. doi:10.1046\/j.1399-0012.2003. 00154.x","DOI":"10.1046\/j.1399-0012.2003.00154.x"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Soleimani M, Rastegar A. Pathophysiology of renal tubular acidosis: core curriculum 2016. Am J Kidney Dis. 2016;68(3):488-498. doi:10.1053\/j.ajkd.2016.03.422","DOI":"10.1053\/j.ajkd.2016.03.422"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol. 2013;37(6):602-612. doi:10.1159\/000351648","DOI":"10.1159\/000351648"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Malvezzi P, Rostaing L. The safety of calcineurin inhibitors for kidney-transplant patients. Expert Opin Drug Saf. 2015;14(10):1531-1546. doi:10.1517\/14740338.2015.1083974","DOI":"10.1517\/14740338.2015.1083974"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med. 1984;311(11):699-705. doi:10.1056\/NEJM198409133111103","DOI":"10.1056\/NEJM198409133111103"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979;2(8151):1033-1036. doi:10.1016\/s0140-6736(79)92440-1","DOI":"10.1016\/S0140-6736(79)92440-1"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Pavleska-Kuzmanovska S, Popov Z, Ivanovski O, et al. Cyclosporine nephrotoxicity and early posttransplant hyperkalemia in living-donor renal recipients: report of 4 cases. Exp Clin Transplant. 2014;12(5):479-483. doi:10.6002\/ect.2013.0159","DOI":"10.6002\/ect.2013.0159"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Sivakumar V, Sriramnaveen P, Krishna C, et al. Role of fludrocortisone in the management of tacrolimus-induced hyperkalemia in a renal transplant recipient. Saudi J Kidney Dis Transpl. 2014;25(1):149-151. doi:10.4103\/1319-2442.124539","DOI":"10.4103\/1319-2442.124539"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Lin W, Mou L, Tu H, et al. Clinical analysis of hyperkalemic renal tubular acidosis caused by calcineurin inhibitors in solid organ transplant recipients. J Clin Pharm Ther. 2017;42(1):122-124. doi:10.1111\/jcpt.12485","DOI":"10.1111\/jcpt.12485"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Rodriguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002;13(8):2160-2170. doi:10.1097\/01.asn.0000023430. 92674.e5","DOI":"10.1097\/01.ASN.0000023430.92674.E5"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Riveiro-Barciela M, Campos-Varela I, Tovar JL, et al. Hyperkalemic distal renal tubular acidosis caused by immunosuppressant treatment with tacrolimus in a liver transplant patient: case report. Transplant Proc. 2011;43(10):4016-4018. doi:10.1016\/j.transproceed.2011.09.064","DOI":"10.1016\/j.transproceed.2011.09.064"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Ogita K, Takada N, Taguchi T, et al. Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report. Asian J Surg. 2003;26(4):218-220. doi:10.1016\/S1015-9584(09)60307-9","DOI":"10.1016\/S1015-9584(09)60307-9"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Dick TB, Raines AA, Stinson JB, Collingridge DS, Harmston GE. Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients. Transplant Proc. 2011;43(7):2664-2668. doi:10.1016\/j.transproceed.2011.07.006","DOI":"10.1016\/j.transproceed.2011.07.006"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Ali SR, Shaheen I, Young D, et al. Fludrocortisone-a treatment for tubulopathy post-paediatric renal transplantation: A national paediatric nephrology unit experience. Pediatr Transplant. 2018;22(2). doi:10.1111\/petr.13134","DOI":"10.1111\/petr.13134"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T04:15:08Z","timestamp":1649304908000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/supplement\/2022\/20\/3\/1\/69\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":19,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2022,3]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.mesot2021.o27","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}